US Capitol Capsule: NIH I-Corps takes startups on focused path to commercialization
This article was originally published in Scrip
Executive Summary
Before Southern California biotech startup BCN Biosciences became engaged with a new program at the National Institutes of Health (NIH), the firm thought it had one indication for its experimental small molecule BCN057 (YEL002) – radiation mitigation.